HRP20050069A2 - Indoline derivatives substituted in position 6, production and use thereof as medicaments - Google Patents
Indoline derivatives substituted in position 6, production and use thereof as medicaments Download PDFInfo
- Publication number
- HRP20050069A2 HRP20050069A2 HR20050069A HRP20050069A HRP20050069A2 HR P20050069 A2 HRP20050069 A2 HR P20050069A2 HR 20050069 A HR20050069 A HR 20050069A HR P20050069 A HRP20050069 A HR P20050069A HR P20050069 A2 HRP20050069 A2 HR P20050069A2
- Authority
- HR
- Croatia
- Prior art keywords
- alkyl
- group
- phenyl
- carbonyl
- amino
- Prior art date
Links
- 239000003814 drug Substances 0.000 title claims description 9
- 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 title 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims description 126
- -1 thiophen-2-yl-carbonyl Chemical group 0.000 claims description 114
- 150000001875 compounds Chemical class 0.000 claims description 113
- 239000000203 mixture Substances 0.000 claims description 56
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 43
- 238000002360 preparation method Methods 0.000 claims description 38
- 150000003839 salts Chemical class 0.000 claims description 23
- 238000006243 chemical reaction Methods 0.000 claims description 22
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 21
- 239000002253 acid Substances 0.000 claims description 19
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 18
- 229910052801 chlorine Inorganic materials 0.000 claims description 17
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 16
- 125000006239 protecting group Chemical group 0.000 claims description 16
- 125000006559 (C1-C3) alkylamino group Chemical group 0.000 claims description 15
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 15
- 239000000460 chlorine Chemical group 0.000 claims description 14
- 238000000034 method Methods 0.000 claims description 14
- 229910052794 bromium Inorganic materials 0.000 claims description 13
- 229910052731 fluorine Inorganic materials 0.000 claims description 13
- 239000011737 fluorine Substances 0.000 claims description 13
- 239000007790 solid phase Substances 0.000 claims description 13
- 125000001841 imino group Chemical group [H]N=* 0.000 claims description 12
- 238000001727 in vivo Methods 0.000 claims description 12
- 150000003951 lactams Chemical group 0.000 claims description 12
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 12
- 125000003282 alkyl amino group Chemical group 0.000 claims description 11
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims description 11
- 229910052757 nitrogen Inorganic materials 0.000 claims description 11
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 9
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 9
- 125000006698 (C1-C3) dialkylamino group Chemical group 0.000 claims description 8
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 claims description 8
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims description 8
- 230000004663 cell proliferation Effects 0.000 claims description 8
- 125000001153 fluoro group Chemical group F* 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 claims description 7
- 125000000217 alkyl group Chemical group 0.000 claims description 7
- 125000003277 amino group Chemical group 0.000 claims description 7
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 claims description 6
- KZBUYRJDOAKODT-UHFFFAOYSA-N Chlorine Chemical group ClCl KZBUYRJDOAKODT-UHFFFAOYSA-N 0.000 claims description 6
- 238000006722 reduction reaction Methods 0.000 claims description 6
- 125000004429 atom Chemical group 0.000 claims description 5
- 125000004663 dialkyl amino group Chemical group 0.000 claims description 5
- 125000005843 halogen group Chemical group 0.000 claims description 5
- 230000007062 hydrolysis Effects 0.000 claims description 5
- 238000006460 hydrolysis reaction Methods 0.000 claims description 5
- 229910052740 iodine Chemical group 0.000 claims description 5
- 125000004430 oxygen atom Chemical group O* 0.000 claims description 5
- 125000004194 piperazin-1-yl group Chemical group [H]N1C([H])([H])C([H])([H])N(*)C([H])([H])C1([H])[H] 0.000 claims description 5
- 125000006594 (C1-C3) alkylsulfony group Chemical group 0.000 claims description 4
- 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 4
- 230000029936 alkylation Effects 0.000 claims description 4
- 238000005804 alkylation reaction Methods 0.000 claims description 4
- 230000009435 amidation Effects 0.000 claims description 4
- 238000007112 amidation reaction Methods 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 239000012876 carrier material Substances 0.000 claims description 4
- 239000003085 diluting agent Substances 0.000 claims description 4
- 229940079593 drug Drugs 0.000 claims description 4
- 230000032050 esterification Effects 0.000 claims description 4
- 238000005886 esterification reaction Methods 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 claims description 4
- 125000001624 naphthyl group Chemical group 0.000 claims description 4
- 229940002612 prodrug Drugs 0.000 claims description 4
- 239000000651 prodrug Substances 0.000 claims description 4
- 125000001424 substituent group Chemical group 0.000 claims description 4
- 125000004214 1-pyrrolidinyl group Chemical group [H]C1([H])N(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 claims description 3
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical compound CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 claims description 3
- DTQVDTLACAAQTR-UHFFFAOYSA-M Trifluoroacetate Chemical compound [O-]C(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-M 0.000 claims description 3
- 125000002252 acyl group Chemical group 0.000 claims description 3
- 230000010933 acylation Effects 0.000 claims description 3
- 238000005917 acylation reaction Methods 0.000 claims description 3
- 125000003545 alkoxy group Chemical group 0.000 claims description 3
- 125000004103 aminoalkyl group Chemical group 0.000 claims description 3
- 125000003710 aryl alkyl group Chemical group 0.000 claims description 3
- 125000004566 azetidin-1-yl group Chemical group N1(CCC1)* 0.000 claims description 3
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 3
- 125000002962 imidazol-1-yl group Chemical group [*]N1C([H])=NC([H])=C1[H] 0.000 claims description 3
- 125000003037 imidazol-2-yl group Chemical group [H]N1C([*])=NC([H])=C1[H] 0.000 claims description 3
- 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 3
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 3
- 238000006277 sulfonation reaction Methods 0.000 claims description 3
- 125000004571 thiomorpholin-4-yl group Chemical group N1(CCSCC1)* 0.000 claims description 3
- JOXIMZWYDAKGHI-UHFFFAOYSA-M toluene-4-sulfonate Chemical compound CC1=CC=C(S([O-])(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-M 0.000 claims description 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims description 2
- 125000006592 (C2-C3) alkenyl group Chemical group 0.000 claims description 2
- 230000002159 abnormal effect Effects 0.000 claims description 2
- 150000001336 alkenes Chemical class 0.000 claims description 2
- 125000005278 alkyl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000005279 aryl sulfonyloxy group Chemical group 0.000 claims description 2
- 125000000051 benzyloxy group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])O* 0.000 claims description 2
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims description 2
- 150000002825 nitriles Chemical class 0.000 claims description 2
- 238000005932 reductive alkylation reaction Methods 0.000 claims description 2
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 16
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 1
- 125000002102 aryl alkyloxo group Chemical group 0.000 claims 1
- 229940126601 medicinal product Drugs 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 270
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 252
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 252
- 239000007858 starting material Substances 0.000 description 82
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 75
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 71
- 239000000741 silica gel Substances 0.000 description 70
- 229910002027 silica gel Inorganic materials 0.000 description 70
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 69
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 69
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 60
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 54
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 53
- 239000002904 solvent Substances 0.000 description 35
- 229910021529 ammonia Inorganic materials 0.000 description 30
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 27
- 238000001819 mass spectrum Methods 0.000 description 27
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 24
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
- 239000002244 precipitate Substances 0.000 description 23
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 22
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 22
- 239000000243 solution Substances 0.000 description 22
- 230000002829 reductive effect Effects 0.000 description 20
- DVFHFXFORJYWPC-UHFFFAOYSA-N 1-acetyl-6-fluoro-3h-indol-2-one Chemical compound C1=C(F)C=C2N(C(=O)C)C(=O)CC2=C1 DVFHFXFORJYWPC-UHFFFAOYSA-N 0.000 description 19
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 19
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 239000012071 phase Substances 0.000 description 18
- 239000000047 product Substances 0.000 description 17
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 15
- 239000003054 catalyst Substances 0.000 description 14
- 210000004027 cell Anatomy 0.000 description 14
- 239000001257 hydrogen Substances 0.000 description 14
- 229910052739 hydrogen Inorganic materials 0.000 description 14
- 238000002844 melting Methods 0.000 description 14
- 230000008018 melting Effects 0.000 description 14
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 13
- 239000003208 petroleum Substances 0.000 description 13
- QOSSAOTZNIDXMA-UHFFFAOYSA-N Dicylcohexylcarbodiimide Chemical compound C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 description 12
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 12
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 12
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 12
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 12
- 239000002585 base Substances 0.000 description 12
- 239000003480 eluent Substances 0.000 description 12
- 150000003254 radicals Chemical class 0.000 description 12
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 11
- 239000011780 sodium chloride Substances 0.000 description 11
- 230000002441 reversible effect Effects 0.000 description 10
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 9
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 9
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 9
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 9
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 8
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 8
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 8
- 229960000583 acetic acid Drugs 0.000 description 8
- 239000004927 clay Substances 0.000 description 8
- 238000001816 cooling Methods 0.000 description 8
- 210000002889 endothelial cell Anatomy 0.000 description 8
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 8
- 229910052938 sodium sulfate Inorganic materials 0.000 description 8
- 235000011152 sodium sulphate Nutrition 0.000 description 8
- SEJDHBXBPUHCFY-UHFFFAOYSA-N 1-acetyl-6-chloro-3h-indol-2-one Chemical compound C1=C(Cl)C=C2N(C(=O)C)C(=O)CC2=C1 SEJDHBXBPUHCFY-UHFFFAOYSA-N 0.000 description 7
- 150000007530 organic bases Chemical class 0.000 description 7
- 230000035755 proliferation Effects 0.000 description 7
- PAYRUJLWNCNPSJ-UHFFFAOYSA-N Aniline Chemical compound NC1=CC=CC=C1 PAYRUJLWNCNPSJ-UHFFFAOYSA-N 0.000 description 6
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 6
- 239000007868 Raney catalyst Substances 0.000 description 6
- 229910000564 Raney nickel Inorganic materials 0.000 description 6
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 description 6
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 6
- 150000007513 acids Chemical class 0.000 description 6
- 239000012074 organic phase Substances 0.000 description 6
- RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 6
- ASOKPJOREAFHNY-UHFFFAOYSA-N 1-Hydroxybenzotriazole Chemical compound C1=CC=C2N(O)N=NC2=C1 ASOKPJOREAFHNY-UHFFFAOYSA-N 0.000 description 5
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 5
- 125000001584 benzyloxycarbonyl group Chemical group C(=O)(OCC1=CC=CC=C1)* 0.000 description 5
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 5
- 239000012362 glacial acetic acid Substances 0.000 description 5
- 238000005984 hydrogenation reaction Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 230000002401 inhibitory effect Effects 0.000 description 5
- 125000006705 (C5-C7) cycloalkyl group Chemical group 0.000 description 4
- VHYFNPMBLIVWCW-UHFFFAOYSA-N 4-Dimethylaminopyridine Chemical compound CN(C)C1=CC=NC=C1 VHYFNPMBLIVWCW-UHFFFAOYSA-N 0.000 description 4
- NNCCQALFJIMRKB-UHFFFAOYSA-N 4-[(dimethylamino)methyl]aniline Chemical compound CN(C)CC1=CC=C(N)C=C1 NNCCQALFJIMRKB-UHFFFAOYSA-N 0.000 description 4
- JARRYVQFBQVOBE-UHFFFAOYSA-N 6-bromo-1,3-dihydroindol-2-one Chemical compound BrC1=CC=C2CC(=O)NC2=C1 JARRYVQFBQVOBE-UHFFFAOYSA-N 0.000 description 4
- 229920002261 Corn starch Polymers 0.000 description 4
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 4
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 229930195725 Mannitol Natural products 0.000 description 4
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 4
- 102000001253 Protein Kinase Human genes 0.000 description 4
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 239000002775 capsule Substances 0.000 description 4
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 4
- IJOOHPMOJXWVHK-UHFFFAOYSA-N chlorotrimethylsilane Chemical compound C[Si](C)(C)Cl IJOOHPMOJXWVHK-UHFFFAOYSA-N 0.000 description 4
- 239000008120 corn starch Substances 0.000 description 4
- 238000011049 filling Methods 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- 235000019359 magnesium stearate Nutrition 0.000 description 4
- 239000000594 mannitol Substances 0.000 description 4
- 235000010355 mannitol Nutrition 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 4
- 108060006633 protein kinase Proteins 0.000 description 4
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 4
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- VZGDMQKNWNREIO-UHFFFAOYSA-N tetrachloromethane Chemical compound ClC(Cl)(Cl)Cl VZGDMQKNWNREIO-UHFFFAOYSA-N 0.000 description 4
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
- 239000008215 water for injection Substances 0.000 description 4
- WDYXTBQUPCLKQQ-UHFFFAOYSA-N 4-(3-methoxy-3-oxopropyl)benzoic acid Chemical compound COC(=O)CCC1=CC=C(C(O)=O)C=C1 WDYXTBQUPCLKQQ-UHFFFAOYSA-N 0.000 description 3
- PKQNTFAOZIVXCE-UHFFFAOYSA-N 6-fluoro-1,3-dihydroindol-2-one Chemical compound FC1=CC=C2CC(=O)NC2=C1 PKQNTFAOZIVXCE-UHFFFAOYSA-N 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
- NQTADLQHYWFPDB-UHFFFAOYSA-N N-Hydroxysuccinimide Chemical compound ON1C(=O)CCC1=O NQTADLQHYWFPDB-UHFFFAOYSA-N 0.000 description 3
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- 239000012317 TBTU Substances 0.000 description 3
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 3
- 229910052783 alkali metal Inorganic materials 0.000 description 3
- 150000001340 alkali metals Chemical class 0.000 description 3
- 230000033115 angiogenesis Effects 0.000 description 3
- 150000008064 anhydrides Chemical class 0.000 description 3
- HQABUPZFAYXKJW-UHFFFAOYSA-N butan-1-amine Chemical compound CCCCN HQABUPZFAYXKJW-UHFFFAOYSA-N 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 238000004587 chromatography analysis Methods 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 3
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 3
- 229960002897 heparin Drugs 0.000 description 3
- 229920000669 heparin Polymers 0.000 description 3
- 125000005928 isopropyloxycarbonyl group Chemical group [H]C([H])([H])C([H])(OC(*)=O)C([H])([H])[H] 0.000 description 3
- 229940043355 kinase inhibitor Drugs 0.000 description 3
- 239000000155 melt Substances 0.000 description 3
- 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 3
- UYWQUFXKFGHYNT-UHFFFAOYSA-N phenylmethyl ester of formic acid Natural products O=COCC1=CC=CC=C1 UYWQUFXKFGHYNT-UHFFFAOYSA-N 0.000 description 3
- 125000001639 phenylmethylene group Chemical group [H]C(=*)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 3
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 239000000829 suppository Substances 0.000 description 3
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 210000004881 tumor cell Anatomy 0.000 description 3
- 108010002164 tyrosine receptor Proteins 0.000 description 3
- NOOLISFMXDJSKH-KXUCPTDWSA-N (-)-Menthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@H]1O NOOLISFMXDJSKH-KXUCPTDWSA-N 0.000 description 2
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 description 2
- 125000004209 (C1-C8) alkyl group Chemical group 0.000 description 2
- HDPNBNXLBDFELL-UHFFFAOYSA-N 1,1,1-trimethoxyethane Chemical compound COC(C)(OC)OC HDPNBNXLBDFELL-UHFFFAOYSA-N 0.000 description 2
- KQFIKPNLZFYYEN-UHFFFAOYSA-N 1-acetyl-2-oxo-3h-indole-6-carbonitrile Chemical compound C1=C(C#N)C=C2N(C(=O)C)C(=O)CC2=C1 KQFIKPNLZFYYEN-UHFFFAOYSA-N 0.000 description 2
- RZNAEYSCOPVDPK-UHFFFAOYSA-N 1-acetyl-3-[(3,4-dimethoxyphenyl)-hydroxymethylidene]-2-oxoindole-6-carbonitrile Chemical compound C1=C(OC)C(OC)=CC=C1C(O)=C1C2=CC=C(C#N)C=C2N(C(C)=O)C1=O RZNAEYSCOPVDPK-UHFFFAOYSA-N 0.000 description 2
- DBYMRQUIWAWJIJ-UHFFFAOYSA-N 1-acetyl-3-[(3,4-dimethoxyphenyl)-methoxymethylidene]-2-oxoindole-6-carbonitrile Chemical compound O=C1N(C(C)=O)C2=CC(C#N)=CC=C2C1=C(OC)C1=CC=C(OC)C(OC)=C1 DBYMRQUIWAWJIJ-UHFFFAOYSA-N 0.000 description 2
- OIGKNMUGQDFQBT-UHFFFAOYSA-N 1-acetyl-6-bromo-3h-indol-2-one Chemical compound C1=C(Br)C=C2N(C(=O)C)C(=O)CC2=C1 OIGKNMUGQDFQBT-UHFFFAOYSA-N 0.000 description 2
- IXOFJBBVLHGAIY-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(3,4-dimethoxyphenyl)-hydroxymethylidene]indol-2-one Chemical compound C1=C(OC)C(OC)=CC=C1C(O)=C1C2=CC=C(Cl)C=C2N(C(C)=O)C1=O IXOFJBBVLHGAIY-UHFFFAOYSA-N 0.000 description 2
- OEGPQRPSKAJWQX-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(3-iodophenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(Cl)=CC=C2C1=C(OC)C1=CC=CC(I)=C1 OEGPQRPSKAJWQX-UHFFFAOYSA-N 0.000 description 2
- QIOYCGAXRBAHEG-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(4-chlorophenyl)-hydroxymethylidene]indol-2-one Chemical compound C12=CC=C(Cl)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(Cl)C=C1 QIOYCGAXRBAHEG-UHFFFAOYSA-N 0.000 description 2
- JRXQLYWVXWLYRF-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[hydroxy-(4-iodophenyl)methylidene]indol-2-one Chemical compound C12=CC=C(Cl)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(I)C=C1 JRXQLYWVXWLYRF-UHFFFAOYSA-N 0.000 description 2
- SCUHKSXHXWORGG-UHFFFAOYSA-N 1-acetyl-6-fluoro-3-[(4-iodophenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=C(I)C=C1 SCUHKSXHXWORGG-UHFFFAOYSA-N 0.000 description 2
- IAJSHXTVMMSREX-UHFFFAOYSA-N 1-acetyl-6-fluoro-3-[hydroxy-(4-iodophenyl)methylidene]indol-2-one Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(I)C=C1 IAJSHXTVMMSREX-UHFFFAOYSA-N 0.000 description 2
- HEWZVZIVELJPQZ-UHFFFAOYSA-N 2,2-dimethoxypropane Chemical compound COC(C)(C)OC HEWZVZIVELJPQZ-UHFFFAOYSA-N 0.000 description 2
- LAFOTQFKZXKMFD-UHFFFAOYSA-N 2-(4-fluoro-2-nitrophenyl)acetic acid Chemical compound OC(=O)CC1=CC=C(F)C=C1[N+]([O-])=O LAFOTQFKZXKMFD-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- UIWLTSQGBOSANU-UHFFFAOYSA-N 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]acetonitrile Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(CC#N)=C1 UIWLTSQGBOSANU-UHFFFAOYSA-N 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- NDVUETYYXRFYKO-UHFFFAOYSA-N 2-oxo-1,3-dihydroindole-6-carbonitrile Chemical compound C1=C(C#N)C=C2NC(=O)CC2=C1 NDVUETYYXRFYKO-UHFFFAOYSA-N 0.000 description 2
- DAUAQNGYDSHRET-UHFFFAOYSA-N 3,4-dimethoxybenzoic acid Chemical compound COC1=CC=C(C(O)=O)C=C1OC DAUAQNGYDSHRET-UHFFFAOYSA-N 0.000 description 2
- KVBWBCRPWVKFQT-UHFFFAOYSA-N 3-iodobenzoic acid Chemical compound OC(=O)C1=CC=CC(I)=C1 KVBWBCRPWVKFQT-UHFFFAOYSA-N 0.000 description 2
- KAXDDSOFSFDHDR-UHFFFAOYSA-N 4-[(1-acetyl-6-chloro-2-oxoindol-3-ylidene)-hydroxymethyl]benzonitrile Chemical compound C12=CC=C(Cl)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(C#N)C=C1 KAXDDSOFSFDHDR-UHFFFAOYSA-N 0.000 description 2
- GHICCUXQJBDNRN-UHFFFAOYSA-N 4-iodobenzoic acid Chemical compound OC(=O)C1=CC=C(I)C=C1 GHICCUXQJBDNRN-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 2
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 2
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 2
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 description 2
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 description 2
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 description 2
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 description 2
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 description 2
- 101001034652 Homo sapiens Insulin-like growth factor 1 receptor Proteins 0.000 description 2
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 description 2
- 101000851018 Homo sapiens Vascular endothelial growth factor receptor 1 Proteins 0.000 description 2
- 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 2
- 101000851030 Homo sapiens Vascular endothelial growth factor receptor 3 Proteins 0.000 description 2
- OAKJQQAXSVQMHS-UHFFFAOYSA-N Hydrazine Chemical compound NN OAKJQQAXSVQMHS-UHFFFAOYSA-N 0.000 description 2
- 102100039688 Insulin-like growth factor 1 receptor Human genes 0.000 description 2
- CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
- BAPJBEWLBFYGME-UHFFFAOYSA-N Methyl acrylate Chemical compound COC(=O)C=C BAPJBEWLBFYGME-UHFFFAOYSA-N 0.000 description 2
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 description 2
- 206010029113 Neovascularisation Diseases 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
- 201000004681 Psoriasis Diseases 0.000 description 2
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- WQDUMFSSJAZKTM-UHFFFAOYSA-N Sodium methoxide Chemical compound [Na+].[O-]C WQDUMFSSJAZKTM-UHFFFAOYSA-N 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- NKANXQFJJICGDU-QPLCGJKRSA-N Tamoxifen Chemical compound C=1C=CC=CC=1C(/CC)=C(C=1C=CC(OCCN(C)C)=CC=1)/C1=CC=CC=C1 NKANXQFJJICGDU-QPLCGJKRSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 description 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 description 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 2
- GPVDHNVGGIAOQT-UHFFFAOYSA-N Veratric acid Natural products COC1=CC=C(C(O)=O)C(OC)=C1 GPVDHNVGGIAOQT-UHFFFAOYSA-N 0.000 description 2
- WETWJCDKMRHUPV-UHFFFAOYSA-N acetyl chloride Chemical compound CC(Cl)=O WETWJCDKMRHUPV-UHFFFAOYSA-N 0.000 description 2
- 239000012346 acetyl chloride Substances 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 125000005907 alkyl ester group Chemical group 0.000 description 2
- 150000001408 amides Chemical class 0.000 description 2
- 235000011114 ammonium hydroxide Nutrition 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- CBHOOMGKXCMKIR-UHFFFAOYSA-N azane;methanol Chemical compound N.OC CBHOOMGKXCMKIR-UHFFFAOYSA-N 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 125000003739 carbamimidoyl group Chemical group C(N)(=N)* 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- PAFZNILMFXTMIY-UHFFFAOYSA-N cyclohexylamine Chemical compound NC1CCCCC1 PAFZNILMFXTMIY-UHFFFAOYSA-N 0.000 description 2
- 239000012024 dehydrating agents Substances 0.000 description 2
- YXDNLQOEZJOXHS-UHFFFAOYSA-N diethyl 2-(4-bromo-2-nitrophenyl)propanedioate Chemical compound CCOC(=O)C(C(=O)OCC)C1=CC=C(Br)C=C1[N+]([O-])=O YXDNLQOEZJOXHS-UHFFFAOYSA-N 0.000 description 2
- VTDCKPNYQDVOLO-UHFFFAOYSA-N dimethyl 2-(4-cyano-2-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C(C#N)C=C1[N+]([O-])=O VTDCKPNYQDVOLO-UHFFFAOYSA-N 0.000 description 2
- YGMYINIHIYQFHB-UHFFFAOYSA-N dimethyl 2-(4-fluoro-2-nitrophenyl)propanedioate Chemical compound COC(=O)C(C(=O)OC)C1=CC=C(F)C=C1[N+]([O-])=O YGMYINIHIYQFHB-UHFFFAOYSA-N 0.000 description 2
- BEPAFCGSDWSTEL-UHFFFAOYSA-N dimethyl malonate Chemical compound COC(=O)CC(=O)OC BEPAFCGSDWSTEL-UHFFFAOYSA-N 0.000 description 2
- YWEUIGNSBFLMFL-UHFFFAOYSA-N diphosphonate Chemical compound O=P(=O)OP(=O)=O YWEUIGNSBFLMFL-UHFFFAOYSA-N 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000004821 distillation Methods 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- WDXLEPSLZXDZDJ-UHFFFAOYSA-N ethyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenoxy]propanoate Chemical compound CCOC(=O)CCOC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 WDXLEPSLZXDZDJ-UHFFFAOYSA-N 0.000 description 2
- WKOAMFPFWSOREG-UHFFFAOYSA-N ethyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 WKOAMFPFWSOREG-UHFFFAOYSA-N 0.000 description 2
- IZRNBWYKVQHOHR-UHFFFAOYSA-N ethyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OCC)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O IZRNBWYKVQHOHR-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 239000012091 fetal bovine serum Substances 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 201000011066 hemangioma Diseases 0.000 description 2
- 210000005260 human cell Anatomy 0.000 description 2
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 2
- 150000007529 inorganic bases Chemical class 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- KWGKDLIKAYFUFQ-UHFFFAOYSA-M lithium chloride Chemical compound [Li+].[Cl-] KWGKDLIKAYFUFQ-UHFFFAOYSA-M 0.000 description 2
- 238000002483 medication Methods 0.000 description 2
- 229940098779 methanesulfonic acid Drugs 0.000 description 2
- FWIITEPZVPNZFL-UHFFFAOYSA-N methyl 2-(4-cyano-2-nitrophenyl)acetate Chemical compound COC(=O)CC1=CC=C(C#N)C=C1[N+]([O-])=O FWIITEPZVPNZFL-UHFFFAOYSA-N 0.000 description 2
- BKUSMEGGTNAKPM-UHFFFAOYSA-N methyl 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 BKUSMEGGTNAKPM-UHFFFAOYSA-N 0.000 description 2
- VAFWROLKXXDPIF-UHFFFAOYSA-N methyl 2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O VAFWROLKXXDPIF-UHFFFAOYSA-N 0.000 description 2
- DJDPBHDSSWYLIR-UHFFFAOYSA-N methyl 2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O DJDPBHDSSWYLIR-UHFFFAOYSA-N 0.000 description 2
- FWYRZRBHUYJAKT-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-bromo-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(O)=C1C2=CC=C(Br)C=C2N(C(C)=O)C1=O FWYRZRBHUYJAKT-UHFFFAOYSA-N 0.000 description 2
- RLMOBUOSQVYNAM-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-chloro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(O)=C1C2=CC=C(Cl)C=C2N(C(C)=O)C1=O RLMOBUOSQVYNAM-UHFFFAOYSA-N 0.000 description 2
- QRYDILTVSIWGPP-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O QRYDILTVSIWGPP-UHFFFAOYSA-N 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- MGZAFDOASDXMRY-UHFFFAOYSA-N n-(4-aminophenyl)-n-methylmethanesulfonamide Chemical compound CS(=O)(=O)N(C)C1=CC=C(N)C=C1 MGZAFDOASDXMRY-UHFFFAOYSA-N 0.000 description 2
- DWXGLGMNSNQXKM-UHFFFAOYSA-N n-[[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]methyl]acetamide Chemical compound CC(=O)NCC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 DWXGLGMNSNQXKM-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000006257 n-butyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000006256 n-propyloxycarbonyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])OC(*)=O 0.000 description 2
- 229910052763 palladium Inorganic materials 0.000 description 2
- LXNAVEXFUKBNMK-UHFFFAOYSA-N palladium(II) acetate Substances [Pd].CC(O)=O.CC(O)=O LXNAVEXFUKBNMK-UHFFFAOYSA-N 0.000 description 2
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical compound [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 description 2
- 125000001148 pentyloxycarbonyl group Chemical group 0.000 description 2
- UHZYTMXLRWXGPK-UHFFFAOYSA-N phosphorus pentachloride Chemical compound ClP(Cl)(Cl)(Cl)Cl UHZYTMXLRWXGPK-UHFFFAOYSA-N 0.000 description 2
- DLYUQMMRRRQYAE-UHFFFAOYSA-N phosphorus pentoxide Inorganic materials O1P(O2)(=O)OP3(=O)OP1(=O)OP2(=O)O3 DLYUQMMRRRQYAE-UHFFFAOYSA-N 0.000 description 2
- FAIAAWCVCHQXDN-UHFFFAOYSA-N phosphorus trichloride Chemical compound ClP(Cl)Cl FAIAAWCVCHQXDN-UHFFFAOYSA-N 0.000 description 2
- 229910052697 platinum Inorganic materials 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 2
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 206010039073 rheumatoid arthritis Diseases 0.000 description 2
- 239000001587 sorbitan monostearate Substances 0.000 description 2
- 235000011076 sorbitan monostearate Nutrition 0.000 description 2
- 229940035048 sorbitan monostearate Drugs 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- WOMMEWZMURUUID-UHFFFAOYSA-N tert-butyl n-[2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]ethyl]carbamate Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(CCNC(=O)OC(C)(C)C)=C1 WOMMEWZMURUUID-UHFFFAOYSA-N 0.000 description 2
- FRGJGHFXVYHSSE-UHFFFAOYSA-N tert-butyl n-[2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]ethyl]carbamate Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(CCNC(=O)OC(C)(C)C)C=C1 FRGJGHFXVYHSSE-UHFFFAOYSA-N 0.000 description 2
- YYSRSJMFEPWMCY-UHFFFAOYSA-N tert-butyl n-[[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]methyl]carbamate Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(CNC(=O)OC(C)(C)C)=C1 YYSRSJMFEPWMCY-UHFFFAOYSA-N 0.000 description 2
- IEOSQWYSYKEHIW-UHFFFAOYSA-N tert-butyl n-[[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]methyl]carbamate Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=C(CNC(=O)OC(C)(C)C)C=C1 IEOSQWYSYKEHIW-UHFFFAOYSA-N 0.000 description 2
- LFQCEHFDDXELDD-UHFFFAOYSA-N tetramethyl orthosilicate Chemical compound CO[Si](OC)(OC)OC LFQCEHFDDXELDD-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 238000007056 transamidation reaction Methods 0.000 description 2
- CWLNAJYDRSIKJS-UHFFFAOYSA-N triethoxymethoxyethane Chemical compound CCOC(OCC)(OCC)OCC CWLNAJYDRSIKJS-UHFFFAOYSA-N 0.000 description 2
- 239000005051 trimethylchlorosilane Substances 0.000 description 2
- COIOYMYWGDAQPM-UHFFFAOYSA-N tris(2-methylphenyl)phosphane Chemical compound CC1=CC=CC=C1P(C=1C(=CC=CC=1)C)C1=CC=CC=C1C COIOYMYWGDAQPM-UHFFFAOYSA-N 0.000 description 2
- 229940075966 (+)- menthol Drugs 0.000 description 1
- NOOLISFMXDJSKH-AEJSXWLSSA-N (+)-menthol Chemical compound CC(C)[C@H]1CC[C@H](C)C[C@@H]1O NOOLISFMXDJSKH-AEJSXWLSSA-N 0.000 description 1
- UKSZBOKPHAQOMP-SVLSSHOZSA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 UKSZBOKPHAQOMP-SVLSSHOZSA-N 0.000 description 1
- QBYIENPQHBMVBV-HFEGYEGKSA-N (2R)-2-hydroxy-2-phenylacetic acid Chemical compound O[C@@H](C(O)=O)c1ccccc1.O[C@@H](C(O)=O)c1ccccc1 QBYIENPQHBMVBV-HFEGYEGKSA-N 0.000 description 1
- AAWZDTNXLSGCEK-LNVDRNJUSA-N (3r,5r)-1,3,4,5-tetrahydroxycyclohexane-1-carboxylic acid Chemical compound O[C@@H]1CC(O)(C(O)=O)C[C@@H](O)C1O AAWZDTNXLSGCEK-LNVDRNJUSA-N 0.000 description 1
- WTBSUAXLZLAHPE-UHFFFAOYSA-N (4-aminophenyl)-(4-methylpiperazin-1-yl)methanone Chemical compound C1CN(C)CCN1C(=O)C1=CC=C(N)C=C1 WTBSUAXLZLAHPE-UHFFFAOYSA-N 0.000 description 1
- 125000004454 (C1-C6) alkoxycarbonyl group Chemical group 0.000 description 1
- 125000004916 (C1-C6) alkylcarbonyl group Chemical group 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- WRGKKASJBOREMB-UHFFFAOYSA-N 1,4-dibromo-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(Br)=CC=C1Br WRGKKASJBOREMB-UHFFFAOYSA-N 0.000 description 1
- XNJAYQHWXYJBBD-UHFFFAOYSA-N 1,4-difluoro-2-nitrobenzene Chemical compound [O-][N+](=O)C1=CC(F)=CC=C1F XNJAYQHWXYJBBD-UHFFFAOYSA-N 0.000 description 1
- BLSBHDGKXZBRRJ-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(3,4-dimethoxyphenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(Cl)=CC=C2C1=C(OC)C1=CC=C(OC)C(OC)=C1 BLSBHDGKXZBRRJ-UHFFFAOYSA-N 0.000 description 1
- YMUYPBUFVFBCAN-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(4-chlorophenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(Cl)=CC=C2C1=C(OC)C1=CC=C(Cl)C=C1 YMUYPBUFVFBCAN-UHFFFAOYSA-N 0.000 description 1
- STDOLCBUPDPYKG-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[(4-iodophenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(Cl)=CC=C2C1=C(OC)C1=CC=C(I)C=C1 STDOLCBUPDPYKG-UHFFFAOYSA-N 0.000 description 1
- VFBMEBJELQQLIG-UHFFFAOYSA-N 1-acetyl-6-chloro-3-[hydroxy-(3-iodophenyl)methylidene]indol-2-one Chemical compound C12=CC=C(Cl)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(I)=C1 VFBMEBJELQQLIG-UHFFFAOYSA-N 0.000 description 1
- YRVBJLMMHKQKKJ-UHFFFAOYSA-N 1-acetyl-6-fluoro-3-[(3-fluorophenyl)-hydroxymethylidene]indol-2-one Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(F)=C1 YRVBJLMMHKQKKJ-UHFFFAOYSA-N 0.000 description 1
- IOJAMRGRHXYUMT-UHFFFAOYSA-N 1-acetyl-6-fluoro-3-[(3-iodophenyl)-methoxymethylidene]indol-2-one Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=CC(I)=C1 IOJAMRGRHXYUMT-UHFFFAOYSA-N 0.000 description 1
- OOCIUMRVPLGZSE-UHFFFAOYSA-N 1-acetyl-6-fluoro-3-[hydroxy-(3-iodophenyl)methylidene]indol-2-one Chemical compound C12=CC=C(F)C=C2N(C(=O)C)C(=O)C1=C(O)C1=CC=CC(I)=C1 OOCIUMRVPLGZSE-UHFFFAOYSA-N 0.000 description 1
- LTMRRSWNXVJMBA-UHFFFAOYSA-L 2,2-diethylpropanedioate Chemical compound CCC(CC)(C([O-])=O)C([O-])=O LTMRRSWNXVJMBA-UHFFFAOYSA-L 0.000 description 1
- JVSFQJZRHXAUGT-UHFFFAOYSA-N 2,2-dimethylpropanoyl chloride Chemical compound CC(C)(C)C(Cl)=O JVSFQJZRHXAUGT-UHFFFAOYSA-N 0.000 description 1
- HIXDQWDOVZUNNA-UHFFFAOYSA-N 2-(3,4-dimethoxyphenyl)-5-hydroxy-7-methoxychromen-4-one Chemical compound C=1C(OC)=CC(O)=C(C(C=2)=O)C=1OC=2C1=CC=C(OC)C(OC)=C1 HIXDQWDOVZUNNA-UHFFFAOYSA-N 0.000 description 1
- KJSCUCDWFWPTAP-UHFFFAOYSA-N 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]acetonitrile Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=CC(CC#N)=C1 KJSCUCDWFWPTAP-UHFFFAOYSA-N 0.000 description 1
- KMGUEILFFWDGFV-UHFFFAOYSA-N 2-benzoyl-2-benzoyloxy-3-hydroxybutanedioic acid Chemical compound C=1C=CC=CC=1C(=O)C(C(C(O)=O)O)(C(O)=O)OC(=O)C1=CC=CC=C1 KMGUEILFFWDGFV-UHFFFAOYSA-N 0.000 description 1
- VABYVFZVTIDNOA-UHFFFAOYSA-N 2-cyclohexylacetyl chloride Chemical compound ClC(=O)CC1CCCCC1 VABYVFZVTIDNOA-UHFFFAOYSA-N 0.000 description 1
- FAFGMAGIYHHRKN-UHFFFAOYSA-N 2-diphenylphosphanylethyl(diphenyl)phosphane;palladium Chemical compound [Pd].C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 FAFGMAGIYHHRKN-UHFFFAOYSA-N 0.000 description 1
- LDJXFZUGZASGIW-UHFFFAOYSA-L 2-diphenylphosphanylethyl(diphenyl)phosphane;palladium(2+);dichloride Chemical compound Cl[Pd]Cl.C=1C=CC=CC=1P(C=1C=CC=CC=1)CCP(C=1C=CC=CC=1)C1=CC=CC=C1 LDJXFZUGZASGIW-UHFFFAOYSA-L 0.000 description 1
- OFTKFKYVSBNYEC-UHFFFAOYSA-N 2-furoyl chloride Chemical compound ClC(=O)C1=CC=CO1 OFTKFKYVSBNYEC-UHFFFAOYSA-N 0.000 description 1
- JJKWHOSQTYYFAE-UHFFFAOYSA-N 2-methoxyacetyl chloride Chemical compound COCC(Cl)=O JJKWHOSQTYYFAE-UHFFFAOYSA-N 0.000 description 1
- RZNHSEZOLFEFGB-UHFFFAOYSA-N 2-methoxybenzoyl chloride Chemical compound COC1=CC=CC=C1C(Cl)=O RZNHSEZOLFEFGB-UHFFFAOYSA-N 0.000 description 1
- DGMOBVGABMBZSB-UHFFFAOYSA-N 2-methylpropanoyl chloride Chemical compound CC(C)C(Cl)=O DGMOBVGABMBZSB-UHFFFAOYSA-N 0.000 description 1
- VMZCDNSFRSVYKQ-UHFFFAOYSA-N 2-phenylacetyl chloride Chemical compound ClC(=O)CC1=CC=CC=C1 VMZCDNSFRSVYKQ-UHFFFAOYSA-N 0.000 description 1
- BUTKIHRNYUEGKB-UHFFFAOYSA-N 3,3-dimethylbutanoyl chloride Chemical compound CC(C)(C)CC(Cl)=O BUTKIHRNYUEGKB-UHFFFAOYSA-N 0.000 description 1
- GAZRNXIMWKZADY-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide Chemical compound CC=1C=C(C)N(C(N)=N)N=1 GAZRNXIMWKZADY-UHFFFAOYSA-N 0.000 description 1
- AGYXIUAGBLMBGV-UHFFFAOYSA-N 3,5-dimethylpyrazole-1-carboximidamide;nitric acid Chemical compound O[N+]([O-])=O.CC=1C=C(C)N(C(N)=N)N=1 AGYXIUAGBLMBGV-UHFFFAOYSA-N 0.000 description 1
- HWVYHIGFOQWPMJ-UHFFFAOYSA-N 3-(2-methoxy-2-oxoethoxy)benzoic acid Chemical compound COC(=O)COC1=CC=CC(C(O)=O)=C1 HWVYHIGFOQWPMJ-UHFFFAOYSA-N 0.000 description 1
- SGFXNNKRAMZCNF-UHFFFAOYSA-N 3-(2-methoxy-2-oxoethyl)benzoic acid Chemical compound COC(=O)CC1=CC=CC(C(O)=O)=C1 SGFXNNKRAMZCNF-UHFFFAOYSA-N 0.000 description 1
- VSFFTIQXOZCOEH-UHFFFAOYSA-N 3-(3-ethoxy-3-oxopropoxy)benzoic acid Chemical compound CCOC(=O)CCOC1=CC=CC(C(O)=O)=C1 VSFFTIQXOZCOEH-UHFFFAOYSA-N 0.000 description 1
- ASRCHPWZOMNVMH-UHFFFAOYSA-N 3-(3-ethoxy-3-oxopropyl)benzoic acid Chemical compound CCOC(=O)CCC1=CC=CC(C(O)=O)=C1 ASRCHPWZOMNVMH-UHFFFAOYSA-N 0.000 description 1
- FKPUNEVVQQPFRF-UHFFFAOYSA-N 3-(3-methoxy-3-oxopropyl)benzoic acid Chemical compound COC(=O)CCC1=CC=CC(C(O)=O)=C1 FKPUNEVVQQPFRF-UHFFFAOYSA-N 0.000 description 1
- IMUIAYCGLVNRQG-UHFFFAOYSA-N 3-(acetamidomethyl)benzoic acid Chemical compound CC(=O)NCC1=CC=CC(C(O)=O)=C1 IMUIAYCGLVNRQG-UHFFFAOYSA-N 0.000 description 1
- DATIHVJZEPOWPT-UHFFFAOYSA-N 3-(cyanomethyl)benzoic acid Chemical compound OC(=O)C1=CC=CC(CC#N)=C1 DATIHVJZEPOWPT-UHFFFAOYSA-N 0.000 description 1
- WOJBIBHVUSZAGS-UHFFFAOYSA-N 3-[(dimethylamino)methyl]aniline Chemical compound CN(C)CC1=CC=CC(N)=C1 WOJBIBHVUSZAGS-UHFFFAOYSA-N 0.000 description 1
- DPFKNLUZGOWEPI-UHFFFAOYSA-N 3-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCCC1=CC=CC(C(O)=O)=C1 DPFKNLUZGOWEPI-UHFFFAOYSA-N 0.000 description 1
- GOCYDCDYEASQGK-DQSJHHFOSA-N 3-[4-[(z)-(6-fluoro-2-oxo-1h-indol-3-ylidene)-[4-(morpholin-4-ylmethyl)anilino]methyl]phenyl]propanoic acid Chemical compound C1=CC(CCC(=O)O)=CC=C1C(\NC=1C=CC(CN2CCOCC2)=CC=1)=C\1C2=CC=C(F)C=C2NC/1=O GOCYDCDYEASQGK-DQSJHHFOSA-N 0.000 description 1
- MQNHKLMHRZYTBZ-UHFFFAOYSA-N 3-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=CC(C(O)=O)=C1 MQNHKLMHRZYTBZ-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MXNBDFWNYRNIBH-UHFFFAOYSA-N 3-fluorobenzoic acid Chemical compound OC(=O)C1=CC=CC(F)=C1 MXNBDFWNYRNIBH-UHFFFAOYSA-N 0.000 description 1
- ISULZYQDGYXDFW-UHFFFAOYSA-N 3-methylbutanoyl chloride Chemical compound CC(C)CC(Cl)=O ISULZYQDGYXDFW-UHFFFAOYSA-N 0.000 description 1
- ROLMZTIHUMKEAI-UHFFFAOYSA-N 4,5-difluoro-2-hydroxybenzonitrile Chemical compound OC1=CC(F)=C(F)C=C1C#N ROLMZTIHUMKEAI-UHFFFAOYSA-N 0.000 description 1
- NVNMCWWSSZFLCY-UHFFFAOYSA-N 4-(1-methylimidazol-2-yl)aniline Chemical compound CN1C=CN=C1C1=CC=C(N)C=C1 NVNMCWWSSZFLCY-UHFFFAOYSA-N 0.000 description 1
- GFUFUJMSZWBPNH-UHFFFAOYSA-N 4-(2-acetamidoethyl)benzoic acid Chemical compound CC(=O)NCCC1=CC=C(C(O)=O)C=C1 GFUFUJMSZWBPNH-UHFFFAOYSA-N 0.000 description 1
- SPBVJVFCFLINPJ-UHFFFAOYSA-N 4-(2-methoxy-2-oxoethoxy)benzoic acid Chemical compound COC(=O)COC1=CC=C(C(O)=O)C=C1 SPBVJVFCFLINPJ-UHFFFAOYSA-N 0.000 description 1
- LUFHLJPQDOKZKU-UHFFFAOYSA-N 4-(2-methoxy-2-oxoethyl)benzoic acid Chemical compound COC(=O)CC1=CC=C(C(O)=O)C=C1 LUFHLJPQDOKZKU-UHFFFAOYSA-N 0.000 description 1
- FCLFVHDYZUXLGI-UHFFFAOYSA-N 4-(3-ethoxy-3-oxopropoxy)benzoic acid Chemical compound CCOC(=O)CCOC1=CC=C(C(O)=O)C=C1 FCLFVHDYZUXLGI-UHFFFAOYSA-N 0.000 description 1
- YBCOJERXUVJAMS-UHFFFAOYSA-N 4-(3-ethoxy-3-oxopropyl)benzoic acid Chemical compound CCOC(=O)CCC1=CC=C(C(O)=O)C=C1 YBCOJERXUVJAMS-UHFFFAOYSA-N 0.000 description 1
- AFHLJRYAVLIEMS-UHFFFAOYSA-N 4-(diethylaminomethyl)aniline Chemical compound CCN(CC)CC1=CC=C(N)C=C1 AFHLJRYAVLIEMS-UHFFFAOYSA-N 0.000 description 1
- DGHAOTHIDTUSJY-UHFFFAOYSA-N 4-(imidazol-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1C=NC=C1 DGHAOTHIDTUSJY-UHFFFAOYSA-N 0.000 description 1
- WNYFVEFUHMDIRQ-UHFFFAOYSA-N 4-(morpholin-4-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCOCC1 WNYFVEFUHMDIRQ-UHFFFAOYSA-N 0.000 description 1
- SFEAIUCOZWDYMJ-UHFFFAOYSA-N 4-(pyrrolidin-1-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCCC1 SFEAIUCOZWDYMJ-UHFFFAOYSA-N 0.000 description 1
- KCEPOOYWVQZKEV-UHFFFAOYSA-N 4-(thiomorpholin-4-ylmethyl)aniline Chemical compound C1=CC(N)=CC=C1CN1CCSCC1 KCEPOOYWVQZKEV-UHFFFAOYSA-N 0.000 description 1
- OEBIVOHKFYSBPE-UHFFFAOYSA-N 4-Benzyloxybenzyl alcohol Chemical compound C1=CC(CO)=CC=C1OCC1=CC=CC=C1 OEBIVOHKFYSBPE-UHFFFAOYSA-N 0.000 description 1
- FHSPDPKBJSGNOC-UHFFFAOYSA-N 4-[(1-acetyl-6-chloro-2-oxoindol-3-ylidene)-chloromethyl]benzonitrile Chemical compound C12=CC=C(Cl)C=C2N(C(=O)C)C(=O)C1=C(Cl)C1=CC=C(C#N)C=C1 FHSPDPKBJSGNOC-UHFFFAOYSA-N 0.000 description 1
- NIXCVBFXLJWUTC-UHFFFAOYSA-N 4-[(4-methylpiperazin-1-yl)methyl]aniline Chemical compound C1CN(C)CCN1CC1=CC=C(N)C=C1 NIXCVBFXLJWUTC-UHFFFAOYSA-N 0.000 description 1
- CCCVQPGAXZNTIL-UHFFFAOYSA-N 4-[2-(dimethylamino)ethoxy]aniline Chemical compound CN(C)CCOC1=CC=C(N)C=C1 CCCVQPGAXZNTIL-UHFFFAOYSA-N 0.000 description 1
- XPKKPVBDOPPWJU-UHFFFAOYSA-N 4-[2-(dimethylamino)ethyl]aniline Chemical compound CN(C)CCC1=CC=C(N)C=C1 XPKKPVBDOPPWJU-UHFFFAOYSA-N 0.000 description 1
- IIHASBWHDACFGZ-UHFFFAOYSA-N 4-[2-[(2-methylpropan-2-yl)oxycarbonylamino]ethyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCCC1=CC=C(C(O)=O)C=C1 IIHASBWHDACFGZ-UHFFFAOYSA-N 0.000 description 1
- LNKHBRDWRIIROP-UHFFFAOYSA-N 4-[[(2-methylpropan-2-yl)oxycarbonylamino]methyl]benzoic acid Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(C(O)=O)C=C1 LNKHBRDWRIIROP-UHFFFAOYSA-N 0.000 description 1
- RIQLJIOFWJEUCA-UHFFFAOYSA-N 4-[[benzyl(methyl)amino]methyl]aniline Chemical compound C=1C=C(N)C=CC=1CN(C)CC1=CC=CC=C1 RIQLJIOFWJEUCA-UHFFFAOYSA-N 0.000 description 1
- JBOSIXUHCCUPHD-UHFFFAOYSA-N 4-[[ethyl(methyl)amino]methyl]aniline Chemical compound CCN(C)CC1=CC=C(N)C=C1 JBOSIXUHCCUPHD-UHFFFAOYSA-N 0.000 description 1
- LNNVDJYHQDDGSD-UHFFFAOYSA-N 4-[[methyl(propyl)amino]methyl]aniline Chemical compound CCCN(C)CC1=CC=C(N)C=C1 LNNVDJYHQDDGSD-UHFFFAOYSA-N 0.000 description 1
- QAZLBEFXKRYWDK-UHFFFAOYSA-N 4-amino-n-[2-(dimethylamino)ethyl]-n-methylbenzamide Chemical compound CN(C)CCN(C)C(=O)C1=CC=C(N)C=C1 QAZLBEFXKRYWDK-UHFFFAOYSA-N 0.000 description 1
- XBLPHYSLHRGMNW-UHFFFAOYSA-N 4-chloro-3-nitrobenzonitrile Chemical compound [O-][N+](=O)C1=CC(C#N)=CC=C1Cl XBLPHYSLHRGMNW-UHFFFAOYSA-N 0.000 description 1
- XRHGYUZYPHTUJZ-UHFFFAOYSA-N 4-chlorobenzoic acid Chemical compound OC(=O)C1=CC=C(Cl)C=C1 XRHGYUZYPHTUJZ-UHFFFAOYSA-N 0.000 description 1
- ADCUEPOHPCPMCE-UHFFFAOYSA-N 4-cyanobenzoic acid Chemical compound OC(=O)C1=CC=C(C#N)C=C1 ADCUEPOHPCPMCE-UHFFFAOYSA-N 0.000 description 1
- UZOVYGYOLBIAJR-UHFFFAOYSA-N 4-isocyanato-4'-methyldiphenylmethane Chemical compound C1=CC(C)=CC=C1CC1=CC=C(N=C=O)C=C1 UZOVYGYOLBIAJR-UHFFFAOYSA-N 0.000 description 1
- BXIJUQJYXZCOFB-UHFFFAOYSA-N 4-n-[2-(dimethylamino)ethyl]-4-n-methylbenzene-1,4-diamine Chemical compound CN(C)CCN(C)C1=CC=C(N)C=C1 BXIJUQJYXZCOFB-UHFFFAOYSA-N 0.000 description 1
- CENVPIZOTHULGJ-UHFFFAOYSA-N 6-chloro-1,3-dihydroindol-2-one Chemical compound ClC1=CC=C2CC(=O)NC2=C1 CENVPIZOTHULGJ-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 1
- 208000003120 Angiofibroma Diseases 0.000 description 1
- 206010003571 Astrocytoma Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 206010005003 Bladder cancer Diseases 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- 206010063209 Chronic allograft nephropathy Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- AAWZDTNXLSGCEK-UHFFFAOYSA-N Cordycepinsaeure Natural products OC1CC(O)(C(O)=O)CC(O)C1O AAWZDTNXLSGCEK-UHFFFAOYSA-N 0.000 description 1
- CMSMOCZEIVJLDB-UHFFFAOYSA-N Cyclophosphamide Chemical compound ClCCN(CCCl)P1(=O)NCCCO1 CMSMOCZEIVJLDB-UHFFFAOYSA-N 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 230000006820 DNA synthesis Effects 0.000 description 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 description 1
- 206010012689 Diabetic retinopathy Diseases 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- 108010041308 Endothelial Growth Factors Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 206010017993 Gastrointestinal neoplasms Diseases 0.000 description 1
- 208000010412 Glaucoma Diseases 0.000 description 1
- 208000032612 Glial tumor Diseases 0.000 description 1
- 206010018338 Glioma Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 1
- 102000014150 Interferons Human genes 0.000 description 1
- 108010050904 Interferons Proteins 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 description 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 description 1
- 239000012448 Lithium borohydride Substances 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- 208000034578 Multiple myelomas Diseases 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- OTCCIMWXFLJLIA-UHFFFAOYSA-N N-acetyl-DL-aspartic acid Natural products CC(=O)NC(C(O)=O)CC(O)=O OTCCIMWXFLJLIA-UHFFFAOYSA-N 0.000 description 1
- OTCCIMWXFLJLIA-BYPYZUCNSA-N N-acetyl-L-aspartic acid Chemical compound CC(=O)N[C@H](C(O)=O)CC(O)=O OTCCIMWXFLJLIA-BYPYZUCNSA-N 0.000 description 1
- RFMMMVDNIPUKGG-YFKPBYRVSA-N N-acetyl-L-glutamic acid Chemical compound CC(=O)N[C@H](C(O)=O)CCC(O)=O RFMMMVDNIPUKGG-YFKPBYRVSA-N 0.000 description 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 229930012538 Paclitaxel Natural products 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 description 1
- 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- AAWZDTNXLSGCEK-ZHQZDSKASA-N Quinic acid Natural products O[C@H]1CC(O)(C(O)=O)C[C@H](O)C1O AAWZDTNXLSGCEK-ZHQZDSKASA-N 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-N R-2-phenyl-2-hydroxyacetic acid Natural products OC(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-N 0.000 description 1
- 206010038563 Reocclusion Diseases 0.000 description 1
- 206010041067 Small cell lung cancer Diseases 0.000 description 1
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- 208000034841 Thrombotic Microangiopathies Diseases 0.000 description 1
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 1
- 206010052779 Transplant rejections Diseases 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 208000008385 Urogenital Neoplasms Diseases 0.000 description 1
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 229940009456 adriamycin Drugs 0.000 description 1
- 125000003158 alcohol group Chemical group 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 150000001347 alkyl bromides Chemical class 0.000 description 1
- 150000001348 alkyl chlorides Chemical class 0.000 description 1
- 150000001351 alkyl iodides Chemical class 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- PASDCCFISLVPSO-UHFFFAOYSA-N benzoyl chloride Chemical compound ClC(=O)C1=CC=CC=C1 PASDCCFISLVPSO-UHFFFAOYSA-N 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- YNHIGQDRGKUECZ-UHFFFAOYSA-L bis(triphenylphosphine)palladium(ii) dichloride Chemical compound [Cl-].[Cl-].[Pd+2].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 YNHIGQDRGKUECZ-UHFFFAOYSA-L 0.000 description 1
- 201000001531 bladder carcinoma Diseases 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
- 125000004063 butyryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 208000035269 cancer or benign tumor Diseases 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 150000001732 carboxylic acid derivatives Chemical class 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- XMPZTFVPEKAKFH-UHFFFAOYSA-P ceric ammonium nitrate Chemical compound [NH4+].[NH4+].[Ce+4].[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O.[O-][N+]([O-])=O XMPZTFVPEKAKFH-UHFFFAOYSA-P 0.000 description 1
- 230000007882 cirrhosis Effects 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 description 1
- 229960004316 cisplatin Drugs 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- XLJMAIOERFSOGZ-UHFFFAOYSA-M cyanate Chemical compound [O-]C#N XLJMAIOERFSOGZ-UHFFFAOYSA-M 0.000 description 1
- JFWMYCVMQSLLOO-UHFFFAOYSA-N cyclobutanecarbonyl chloride Chemical compound ClC(=O)C1CCC1 JFWMYCVMQSLLOO-UHFFFAOYSA-N 0.000 description 1
- RVOJTCZRIKWHDX-UHFFFAOYSA-N cyclohexanecarbonyl chloride Chemical compound ClC(=O)C1CCCCC1 RVOJTCZRIKWHDX-UHFFFAOYSA-N 0.000 description 1
- 229960004397 cyclophosphamide Drugs 0.000 description 1
- ZOOSILUVXHVRJE-UHFFFAOYSA-N cyclopropanecarbonyl chloride Chemical compound ClC(=O)C1CC1 ZOOSILUVXHVRJE-UHFFFAOYSA-N 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 208000033679 diabetic kidney disease Diseases 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- IQDGSYLLQPDQDV-UHFFFAOYSA-N dimethylazanium;chloride Chemical compound Cl.CNC IQDGSYLLQPDQDV-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 239000003534 dna topoisomerase inhibitor Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 201000005619 esophageal carcinoma Diseases 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- JTWXVYSMVQXPEA-UHFFFAOYSA-N ethyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenoxy]propanoate Chemical compound CCOC(=O)CCOC1=CC=CC(C(OC)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 JTWXVYSMVQXPEA-UHFFFAOYSA-N 0.000 description 1
- LXQCSXYHZBBBCP-UHFFFAOYSA-N ethyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound CCOC(=O)CCC1=CC=CC(C(OC)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 LXQCSXYHZBBBCP-UHFFFAOYSA-N 0.000 description 1
- DBXWBERRJWGIAH-UHFFFAOYSA-N ethyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenoxy]propanoate Chemical compound C1=CC(OCCC(=O)OCC)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O DBXWBERRJWGIAH-UHFFFAOYSA-N 0.000 description 1
- HFTMFOKWYVJCQC-UHFFFAOYSA-N ethyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenoxy]propanoate Chemical compound C1=CC(OCCC(=O)OCC)=CC=C1C(OC)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O HFTMFOKWYVJCQC-UHFFFAOYSA-N 0.000 description 1
- PYMCTBPOKGCGFV-UHFFFAOYSA-N ethyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OCC)=CC=C1C(OC)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O PYMCTBPOKGCGFV-UHFFFAOYSA-N 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 230000003176 fibrotic effect Effects 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical compound C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 description 1
- 229940080856 gleevec Drugs 0.000 description 1
- 208000005017 glioblastoma Diseases 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 150000004820 halides Chemical class 0.000 description 1
- 201000003911 head and neck carcinoma Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 229940022353 herceptin Drugs 0.000 description 1
- 125000003104 hexanoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000005935 hexyloxycarbonyl group Chemical group 0.000 description 1
- 239000003667 hormone antagonist Substances 0.000 description 1
- 102000058223 human VEGFA Human genes 0.000 description 1
- 150000002431 hydrogen Chemical class 0.000 description 1
- 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 description 1
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 description 1
- JBFYUZGYRGXSFL-UHFFFAOYSA-N imidazolide Chemical compound C1=C[N-]C=N1 JBFYUZGYRGXSFL-UHFFFAOYSA-N 0.000 description 1
- 238000002513 implantation Methods 0.000 description 1
- JYGFTBXVXVMTGB-UHFFFAOYSA-N indolin-2-one Chemical class C1=CC=C2NC(=O)CC2=C1 JYGFTBXVXVMTGB-UHFFFAOYSA-N 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940047124 interferons Drugs 0.000 description 1
- INQOMBQAUSQDDS-UHFFFAOYSA-N iodomethane Chemical compound IC INQOMBQAUSQDDS-UHFFFAOYSA-N 0.000 description 1
- 229940084651 iressa Drugs 0.000 description 1
- 239000012948 isocyanate Substances 0.000 description 1
- 150000002513 isocyanates Chemical class 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960004873 levomenthol Drugs 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- XGZVUEUWXADBQD-UHFFFAOYSA-L lithium carbonate Chemical compound [Li+].[Li+].[O-]C([O-])=O XGZVUEUWXADBQD-UHFFFAOYSA-L 0.000 description 1
- 229910052808 lithium carbonate Inorganic materials 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 201000005296 lung carcinoma Diseases 0.000 description 1
- 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
- 235000019341 magnesium sulphate Nutrition 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229960002510 mandelic acid Drugs 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 210000003584 mesangial cell Anatomy 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052987 metal hydride Inorganic materials 0.000 description 1
- 150000004681 metal hydrides Chemical class 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 1
- WQQVYSFGKJHNTF-UHFFFAOYSA-N methyl 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 WQQVYSFGKJHNTF-UHFFFAOYSA-N 0.000 description 1
- PSRKIEFOOREYPK-UHFFFAOYSA-N methyl 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenoxy]acetate Chemical compound COC(=O)COC1=CC=CC(C(OC)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 PSRKIEFOOREYPK-UHFFFAOYSA-N 0.000 description 1
- YGMUAESDJSJCGK-UHFFFAOYSA-N methyl 2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]acetate Chemical compound COC(=O)CC1=CC=CC(C(OC)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 YGMUAESDJSJCGK-UHFFFAOYSA-N 0.000 description 1
- IAASPGPQXUZZLW-UHFFFAOYSA-N methyl 2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenoxy]acetate Chemical compound C1=CC(OCC(=O)OC)=CC=C1C(OC)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O IAASPGPQXUZZLW-UHFFFAOYSA-N 0.000 description 1
- WEZRWHJFUGGUSI-UHFFFAOYSA-N methyl 2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]acetate Chemical compound C1=CC(CC(=O)OC)=CC=C1C(OC)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O WEZRWHJFUGGUSI-UHFFFAOYSA-N 0.000 description 1
- ALJUXZQJOKIMLE-UHFFFAOYSA-N methyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(C(O)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 ALJUXZQJOKIMLE-UHFFFAOYSA-N 0.000 description 1
- GALUOOCYCHMHSF-UHFFFAOYSA-N methyl 3-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound COC(=O)CCC1=CC=CC(C(OC)=C2C3=CC=C(F)C=C3N(C(C)=O)C2=O)=C1 GALUOOCYCHMHSF-UHFFFAOYSA-N 0.000 description 1
- ANKLQIIAYRLROM-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-bromo-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(OC)=C1C2=CC=C(Br)C=C2N(C(C)=O)C1=O ANKLQIIAYRLROM-UHFFFAOYSA-N 0.000 description 1
- ZZKCPQIEJFMTRB-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-chloro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(OC)=C1C2=CC=C(Cl)C=C2N(C(C)=O)C1=O ZZKCPQIEJFMTRB-UHFFFAOYSA-N 0.000 description 1
- MFAQSOAWUAWNDO-UHFFFAOYSA-N methyl 3-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]propanoate Chemical compound C1=CC(CCC(=O)OC)=CC=C1C(OC)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O MFAQSOAWUAWNDO-UHFFFAOYSA-N 0.000 description 1
- NQMRYBIKMRVZLB-UHFFFAOYSA-N methylamine hydrochloride Chemical compound [Cl-].[NH3+]C NQMRYBIKMRVZLB-UHFFFAOYSA-N 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- BFUKNKGBMCOSDK-UHFFFAOYSA-N n'-[(4-aminophenyl)methyl]-n,n,n'-trimethylethane-1,2-diamine Chemical compound CN(C)CCN(C)CC1=CC=C(N)C=C1 BFUKNKGBMCOSDK-UHFFFAOYSA-N 0.000 description 1
- ULWOJODHECIZAU-UHFFFAOYSA-N n,n-diethylpropan-2-amine Chemical compound CCN(CC)C(C)C ULWOJODHECIZAU-UHFFFAOYSA-N 0.000 description 1
- FXTJCYDXMWCGAE-UHFFFAOYSA-N n-(4-aminophenyl)-2-(dimethylamino)-n-methylacetamide Chemical compound CN(C)CC(=O)N(C)C1=CC=C(N)C=C1 FXTJCYDXMWCGAE-UHFFFAOYSA-N 0.000 description 1
- NRCLQRUDKZTTER-UHFFFAOYSA-N n-(4-aminophenyl)-3-(dimethylamino)-n-methylpropanamide Chemical compound CN(C)CCC(=O)N(C)C1=CC=C(N)C=C1 NRCLQRUDKZTTER-UHFFFAOYSA-N 0.000 description 1
- DSXMDFJEUSOVSG-UHFFFAOYSA-N n-(4-aminophenyl)-4-(dimethylamino)-n-methylbutanamide Chemical compound CN(C)CCCC(=O)N(C)C1=CC=C(N)C=C1 DSXMDFJEUSOVSG-UHFFFAOYSA-N 0.000 description 1
- WVLGLCDJANXERT-UHFFFAOYSA-N n-(4-aminophenyl)-5-(dimethylamino)-n-methylpentanamide Chemical compound CN(C)CCCCC(=O)N(C)C1=CC=C(N)C=C1 WVLGLCDJANXERT-UHFFFAOYSA-N 0.000 description 1
- ZVQDUTWWGNEURB-UHFFFAOYSA-N n-(4-aminophenyl)-n-[2-(dimethylamino)ethyl]acetamide Chemical compound CN(C)CCN(C(C)=O)C1=CC=C(N)C=C1 ZVQDUTWWGNEURB-UHFFFAOYSA-N 0.000 description 1
- TXCOFUNEYLUKHR-UHFFFAOYSA-N n-(4-aminophenyl)-n-[2-(dimethylamino)ethyl]methanesulfonamide Chemical compound CN(C)CCN(S(C)(=O)=O)C1=CC=C(N)C=C1 TXCOFUNEYLUKHR-UHFFFAOYSA-N 0.000 description 1
- WFWDHVMQQIVLNN-UHFFFAOYSA-N n-(4-aminophenyl)-n-[3-(dimethylamino)propyl]acetamide Chemical compound CN(C)CCCN(C(C)=O)C1=CC=C(N)C=C1 WFWDHVMQQIVLNN-UHFFFAOYSA-N 0.000 description 1
- LBWNQLVDYPNHAV-UHFFFAOYSA-N n-(4-aminophenyl)-n-methyl-2-(4-methylpiperazin-1-yl)acetamide Chemical compound C=1C=C(N)C=CC=1N(C)C(=O)CN1CCN(C)CC1 LBWNQLVDYPNHAV-UHFFFAOYSA-N 0.000 description 1
- BXIOBQGZUQCPCJ-UHFFFAOYSA-N n-[2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-hydroxymethyl]phenyl]ethyl]acetamide Chemical compound C1=CC(CCNC(=O)C)=CC=C1C(O)=C1C2=CC=C(F)C=C2N(C(C)=O)C1=O BXIOBQGZUQCPCJ-UHFFFAOYSA-N 0.000 description 1
- HFSIHLNWDFDOKE-UHFFFAOYSA-N n-[2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]ethyl]acetamide Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=C(CCNC(C)=O)C=C1 HFSIHLNWDFDOKE-UHFFFAOYSA-N 0.000 description 1
- IZRSCYGLWHARLD-UHFFFAOYSA-N n-[[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]methyl]acetamide Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=CC(CNC(C)=O)=C1 IZRSCYGLWHARLD-UHFFFAOYSA-N 0.000 description 1
- 201000003142 neovascular glaucoma Diseases 0.000 description 1
- 201000009925 nephrosclerosis Diseases 0.000 description 1
- 210000000944 nerve tissue Anatomy 0.000 description 1
- 150000007523 nucleic acids Chemical class 0.000 description 1
- 102000039446 nucleic acids Human genes 0.000 description 1
- 108020004707 nucleic acids Proteins 0.000 description 1
- JKNKNWJNCOJPLI-UHFFFAOYSA-N o-phthalaldehydic acid Chemical compound C1=CC=C2C(O)OC(=O)C2=C1 JKNKNWJNCOJPLI-UHFFFAOYSA-N 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 229960001592 paclitaxel Drugs 0.000 description 1
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 1
- QJPQVXSHYBGQGM-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 QJPQVXSHYBGQGM-UHFFFAOYSA-N 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 125000005544 phthalimido group Chemical group 0.000 description 1
- 125000001557 phthalyl group Chemical group C(=O)(O)C1=C(C(=O)*)C=CC=C1 0.000 description 1
- 229910000027 potassium carbonate Inorganic materials 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 150000003141 primary amines Chemical class 0.000 description 1
- RZWZRACFZGVKFM-UHFFFAOYSA-N propanoyl chloride Chemical compound CCC(Cl)=O RZWZRACFZGVKFM-UHFFFAOYSA-N 0.000 description 1
- 125000001501 propionyl group Chemical group O=C([*])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004742 propyloxycarbonyl group Chemical group 0.000 description 1
- PSAYJRPASWETSH-UHFFFAOYSA-N pyridine-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CC=N1 PSAYJRPASWETSH-UHFFFAOYSA-N 0.000 description 1
- ATBIAJXSKNPHEI-UHFFFAOYSA-N pyridine-3-carbonyl chloride Chemical compound ClC(=O)C1=CC=CN=C1 ATBIAJXSKNPHEI-UHFFFAOYSA-N 0.000 description 1
- RVQZKNOMKUSGCI-UHFFFAOYSA-N pyridine-4-carbonyl chloride Chemical compound ClC(=O)C1=CC=NC=C1 RVQZKNOMKUSGCI-UHFFFAOYSA-N 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 208000000587 small cell lung carcinoma Diseases 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- BEOOHQFXGBMRKU-UHFFFAOYSA-N sodium cyanoborohydride Chemical compound [Na+].[B-]C#N BEOOHQFXGBMRKU-UHFFFAOYSA-N 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 229960001603 tamoxifen Drugs 0.000 description 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 1
- ZTYRRWNDQSVOCL-UHFFFAOYSA-N tert-butyl 4-[(4-aminophenyl)methyl]piperazine-1-carboxylate Chemical compound C1CN(C(=O)OC(C)(C)C)CCN1CC1=CC=C(N)C=C1 ZTYRRWNDQSVOCL-UHFFFAOYSA-N 0.000 description 1
- PSBBYCGCULPBHU-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]-n-ethylcarbamate Chemical compound CC(C)(C)OC(=O)N(CC)CC1=CC=C(N)C=C1 PSBBYCGCULPBHU-UHFFFAOYSA-N 0.000 description 1
- ZXZZEBPOSRKQAU-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]-n-methylcarbamate Chemical compound CC(C)(C)OC(=O)N(C)CC1=CC=C(N)C=C1 ZXZZEBPOSRKQAU-UHFFFAOYSA-N 0.000 description 1
- UXWQXBSQQHAGMG-UHFFFAOYSA-N tert-butyl n-[(4-aminophenyl)methyl]carbamate Chemical compound CC(C)(C)OC(=O)NCC1=CC=C(N)C=C1 UXWQXBSQQHAGMG-UHFFFAOYSA-N 0.000 description 1
- FNZVRZBSIVNINH-UHFFFAOYSA-N tert-butyl n-[2-[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]ethyl]carbamate Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=CC(CCNC(=O)OC(C)(C)C)=C1 FNZVRZBSIVNINH-UHFFFAOYSA-N 0.000 description 1
- ZDPUCPOFIROEBM-UHFFFAOYSA-N tert-butyl n-[2-[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]ethyl]carbamate Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=C(CCNC(=O)OC(C)(C)C)C=C1 ZDPUCPOFIROEBM-UHFFFAOYSA-N 0.000 description 1
- VZMWKCCJSJIGLD-UHFFFAOYSA-N tert-butyl n-[[3-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]methyl]carbamate Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=CC(CNC(=O)OC(C)(C)C)=C1 VZMWKCCJSJIGLD-UHFFFAOYSA-N 0.000 description 1
- WWLUTDXPZPEERD-UHFFFAOYSA-N tert-butyl n-[[4-[(1-acetyl-6-fluoro-2-oxoindol-3-ylidene)-methoxymethyl]phenyl]methyl]carbamate Chemical compound O=C1N(C(C)=O)C2=CC(F)=CC=C2C1=C(OC)C1=CC=C(CNC(=O)OC(C)(C)C)C=C1 WWLUTDXPZPEERD-UHFFFAOYSA-N 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 125000001412 tetrahydropyranyl group Chemical group 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- QIQITDHWZYEEPA-UHFFFAOYSA-N thiophene-2-carbonyl chloride Chemical compound ClC(=O)C1=CC=CS1 QIQITDHWZYEEPA-UHFFFAOYSA-N 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 229940044693 topoisomerase inhibitor Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 125000000026 trimethylsilyl group Chemical group [H]C([H])([H])[Si]([*])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- BWHDROKFUHTORW-UHFFFAOYSA-N tritert-butylphosphane Chemical compound CC(C)(C)P(C(C)(C)C)C(C)(C)C BWHDROKFUHTORW-UHFFFAOYSA-N 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 208000010570 urinary bladder carcinoma Diseases 0.000 description 1
- 208000037964 urogenital cancer Diseases 0.000 description 1
- 125000003774 valeryl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229960003048 vinblastine Drugs 0.000 description 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/32—Oxygen atoms
- C07D209/34—Oxygen atoms in position 2
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Ophthalmology & Optometry (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Oncology (AREA)
- Neurosurgery (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10233366A DE10233366A1 (de) | 2002-07-23 | 2002-07-23 | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
DE10328533A DE10328533A1 (de) | 2003-06-24 | 2003-06-24 | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
PCT/EP2003/007961 WO2004009547A1 (fr) | 2002-07-23 | 2003-07-22 | Derives d'indolinone substitues en position 6, leur preparation et leur utilisation comme medicaments |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20050069A2 true HRP20050069A2 (en) | 2005-12-31 |
Family
ID=30771725
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HR20050069A HRP20050069A2 (en) | 2002-07-23 | 2005-01-21 | Indoline derivatives substituted in position 6, production and use thereof as medicaments |
Country Status (25)
Country | Link |
---|---|
EP (1) | EP1523473B1 (fr) |
JP (1) | JP4401291B2 (fr) |
KR (2) | KR20050052456A (fr) |
CN (1) | CN1318403C (fr) |
AR (1) | AR041188A1 (fr) |
AU (2) | AU2003254557B2 (fr) |
BR (1) | BR0312799A (fr) |
CA (1) | CA2493436C (fr) |
DK (1) | DK1523473T3 (fr) |
EA (1) | EA008623B1 (fr) |
EC (1) | ECSP055567A (fr) |
ES (1) | ES2409062T3 (fr) |
HK (1) | HK1081554A1 (fr) |
HR (1) | HRP20050069A2 (fr) |
IL (1) | IL166404A0 (fr) |
MX (1) | MXPA04012937A (fr) |
MY (1) | MY138141A (fr) |
NO (1) | NO20050937L (fr) |
PE (1) | PE20040701A1 (fr) |
PL (2) | PL374879A1 (fr) |
RS (1) | RS20050047A (fr) |
SA (1) | SA03240430B1 (fr) |
TW (1) | TWI343375B (fr) |
UY (1) | UY27903A1 (fr) |
WO (1) | WO2004009547A1 (fr) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7169936B2 (en) | 2002-07-23 | 2007-01-30 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments |
US7514468B2 (en) | 2002-07-23 | 2009-04-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions |
US20060058311A1 (en) * | 2004-08-14 | 2006-03-16 | Boehringer Ingelheim International Gmbh | Combinations for the treatment of diseases involving cell proliferation |
PE20061155A1 (es) * | 2004-12-24 | 2006-12-16 | Boehringer Ingelheim Int | Derivados de indolinona como agentes para el tratamiento o la prevencion de enfermedades fibroticas |
KR20080007645A (ko) | 2005-04-28 | 2008-01-22 | 베링거 인겔하임 인터내셔날 게엠베하 | 염증성 질환 치료용 신규 화합물 |
WO2007057399A2 (fr) * | 2005-11-15 | 2007-05-24 | Boehringer Ingelheim International Gmbh | Traitement du cancer |
JP2011510031A (ja) * | 2008-01-25 | 2011-03-31 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 6−フルオロ−1,2−ジヒドロ−2−オキソ−3h−インドール−3−イリデン誘導体の製造方法 |
ES2394239T3 (es) * | 2008-01-25 | 2013-01-23 | Boehringer Ingelheim International Gmbh | Formas salinas de un derivado de 6-fluoro-1,2-dihidro-2-oxo-3H-indol-3-ilideno, procedimiento para su preparación y composiciones farmacéuticas que las contienen |
PE20110213A1 (es) | 2008-07-29 | 2011-04-16 | Boehringer Ingelheim Int | Derivados de indolinona como inhibidores de quinasa |
EP2910547B1 (fr) * | 2012-10-17 | 2017-06-14 | Okayama University | Composé, tautomère et isomère géométrique de celui-ci, sel dudit composé, tautomère ou isomère géométrique, procédé de fabrication dudit composé, tautomère, isomère ou sel, ainsi qu'agent antimicrobien et médicament anti-infectieux |
EP2930167B1 (fr) | 2012-12-06 | 2018-11-21 | KBP Biosciences Co., Ltd. | Dérivés d'indolinone tenant lieu d'inhibiteurs de la tyrosine kinase |
CN105461609B (zh) * | 2015-12-25 | 2019-08-23 | 杭州新博思生物医药有限公司 | 一种尼达尼布的制备方法 |
CN114213396B (zh) * | 2022-01-27 | 2023-03-24 | 深圳市乐土生物医药有限公司 | 一种吲哚-2-酮类化合物及其制备方法与用途 |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE243195T1 (de) * | 1998-09-25 | 2003-07-15 | Boehringer Ingelheim Pharma | Neue substituierte indolinone mit einer inhibierenden wirkung auf verschiedene kinasen und cyclin/cdk-komplexe |
GB9904933D0 (en) * | 1999-03-04 | 1999-04-28 | Glaxo Group Ltd | Compounds |
US7005444B2 (en) * | 2001-09-27 | 2006-02-28 | Allergan, Inc. | 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors |
WO2003027102A1 (fr) * | 2001-09-27 | 2003-04-03 | Allergan, Inc. | L'utilisation de 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones en tant qu'inhibiteurs de kinases |
-
2003
- 2003-07-21 PE PE2003000724A patent/PE20040701A1/es not_active Application Discontinuation
- 2003-07-22 PL PL03374879A patent/PL374879A1/xx unknown
- 2003-07-22 TW TW092119987A patent/TWI343375B/zh not_active IP Right Cessation
- 2003-07-22 MY MYPI20032755A patent/MY138141A/en unknown
- 2003-07-22 WO PCT/EP2003/007961 patent/WO2004009547A1/fr active Application Filing
- 2003-07-22 RS YUP-2005/0047A patent/RS20050047A/sr unknown
- 2003-07-22 CN CNB038173174A patent/CN1318403C/zh not_active Expired - Fee Related
- 2003-07-22 KR KR1020057001222A patent/KR20050052456A/ko active IP Right Grant
- 2003-07-22 BR BR0312799-0A patent/BR0312799A/pt not_active Expired - Fee Related
- 2003-07-22 CA CA2493436A patent/CA2493436C/fr not_active Expired - Fee Related
- 2003-07-22 AU AU2003254557A patent/AU2003254557B2/en not_active Ceased
- 2003-07-22 PL PL397821A patent/PL397821A1/pl unknown
- 2003-07-22 ES ES03765079T patent/ES2409062T3/es not_active Expired - Lifetime
- 2003-07-22 DK DK03765079.3T patent/DK1523473T3/da active
- 2003-07-22 JP JP2004522540A patent/JP4401291B2/ja not_active Expired - Fee Related
- 2003-07-22 EA EA200500148A patent/EA008623B1/ru not_active IP Right Cessation
- 2003-07-22 KR KR1020117030702A patent/KR20120003025A/ko not_active Application Discontinuation
- 2003-07-22 MX MXPA04012937A patent/MXPA04012937A/es active IP Right Grant
- 2003-07-22 EP EP03765079A patent/EP1523473B1/fr not_active Expired - Lifetime
- 2003-07-23 UY UY27903A patent/UY27903A1/es not_active Application Discontinuation
- 2003-07-23 AR ARP030102634A patent/AR041188A1/es not_active Suspension/Interruption
- 2003-12-07 SA SA3240430A patent/SA03240430B1/ar unknown
-
2005
- 2005-01-20 IL IL16640405A patent/IL166404A0/xx not_active IP Right Cessation
- 2005-01-21 HR HR20050069A patent/HRP20050069A2/hr not_active Application Discontinuation
- 2005-01-24 EC EC2005005567A patent/ECSP055567A/es unknown
- 2005-02-21 NO NO20050937A patent/NO20050937L/no not_active Application Discontinuation
-
2006
- 2006-02-16 HK HK06101988A patent/HK1081554A1/xx not_active IP Right Cessation
-
2010
- 2010-07-06 AU AU2010202845A patent/AU2010202845A1/en not_active Ceased
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20050069A2 (en) | Indoline derivatives substituted in position 6, production and use thereof as medicaments | |
US7547703B2 (en) | Indoline derivatives substituted in the 6-position, their preparation and their use as medicaments | |
KR100857734B1 (ko) | 6위치가 치환된 인돌리논, 이를 포함하는 약제학적 조성물및 이의 제조방법 | |
JP2003508394A (ja) | 新規な置換インドリノン類、その製造及びその薬剤としての使用 | |
JP2006501273A (ja) | ヘテロ環置換インドリノン、その製法及び薬物としてのその使用 | |
JP2004525173A (ja) | 6位で置換されたインドリノン、それらのキナーゼインヒビターとしての使用 | |
EP0923551A1 (fr) | Derives de 4-aminoethoxy indolone | |
JP2005537276A (ja) | 6−置換インドリノン誘導体、その製法及び医薬組成物としての使用 | |
NZ538337A (en) | Indolinone derivatives substituted in position 6, production and use thereof as medicaments for treating abnormal cell proliferation | |
DE10328533A1 (de) | In 6-Stellung substituierte Indolinonderivate, ihre Herstellung und ihre Verwendung als Arzneimittel |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A1OB | Publication of a patent application | ||
ARAI | Request for the grant of a patent on the basis of the submitted results of a substantive examination of a patent application | ||
ODRP | Renewal fee for the maintenance of a patent |
Payment date: 20120626 Year of fee payment: 10 |
|
OBST | Application withdrawn |